IMMUNOHISTOCHEMISTRY, CD 10

The Immunohistochemistry (IHC) – CD10 test is a specialized diagnostic test used to detect CD10 protein expression in tissue samples. CD10, also known as Common Acute Lymphoblastic Leukemia Antigen (CALLA), is a cell surface enzyme expressed in certain normal and abnormal cells, especially in lymphoid tissues and specific epithelial structures.

This test is widely used in hematopathology and oncologic pathology to diagnose and classify several cancers, particularly lymphomas, leukemias, and selected epithelial tumors. Detecting CD10 helps pathologists determine tumor origin, classify cell type, and differentiate between various disease subtypes.

The CD10 marker is especially useful in diagnosing:

• Follicular lymphoma
• Diffuse large B-cell lymphoma (DLBCL)
• Acute lymphoblastic leukemia (ALL)
• Certain renal cell carcinomas
• Some endometrial stromal tumors

CD10 expression is valuable in identifying germinal center B-cell origin, which helps classify lymphoma subtypes and may provide prognostic information.

The CD10 IHC test is often performed alongside other markers such as CD20, BCL2, BCL6, CD3, MUM1, and Ki-67 for complete tissue characterization.

Benefits of the Test

The CD10 test offers several important clinical benefits:

• Detects CD10 protein expression accurately
• Helps classify lymphomas and leukemias
• Supports epithelial and stromal tumor diagnosis
• Assists in determining tumor origin
• Improves diagnostic precision
• Helps guide treatment planning

This test is essential for accurate pathology diagnosis.

Why Doctors Recommend This Test

Doctors recommend the CD10 test when detailed tumor classification is required.

It is commonly advised for:

• Suspected lymphoma diagnosis
• Leukemia tissue evaluation
• Germinal center lymphoma classification
• Endometrial stromal lesion assessment
• Complex pathology confirmation cases

The results help hematologists and oncologists make informed treatment decisions.

Preparation Before Test

No special preparation is required from the patient. The test is performed on previously collected tissue biopsy or surgical specimens.

Normal Reporting Time

The usual turnaround time for the CD10 IHC test is 2 to 5 working days, depending on tissue complexity and laboratory workflow.

Who Should Take This Test

This test is recommended for:

• Patients with suspected lymphoma or leukemia
• Individuals requiring tumor subtype classification
• Patients with abnormal lymphoid tissue findings
• Cases requiring tissue origin identification
• Oncology patients needing precise diagnosis

The IHC CD10 test is an essential diagnostic tool in pathology. It supports accurate tumor classification, improves diagnostic confidence, and helps guide personalized treatment planning.